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Abstract Previous phytochemical investigation of the leaves and seeds of Pittosporum angustifolium Lodd. led to the
isolation and structural elucidation of polyphenols and triterpene saponins. Evaluation for cytotoxicity of isolated saponins
revealed that the predominant structural feature for a cytotoxic activity are acyl substituents at the oleanane aglycon
backbone. The present work reports the results of a screening of 10 selected acylated saponins for their potential to inhibit
the human DNA-topoisomerase I, giving rise to IC50 values in a range of 2.8–46.5 lM. To clarify the mode of observed
cytotoxic action and, moreover, to distinguish from a pure surfactant effect which is commonly accompanied with
saponins, these results indicate an involvement of the topoisomerase I and its role as a possible target structure for a
cytotoxic activity. In addition, computational predictions of the fitting of saponins to the topoisomerase I–DNA complex,
indicate a similar binding mode to that of clinically used topoisomerase I inhibitors.
Graphical Abstract Ten acylated triterpene saponins from Pittosporum angustifolium were investigated for their potential
to inhibit the human DNA-topoisomerase I and computational predictions of the fitting of saponins to the topoisomerase I–
DNA complex were carried out.
C. Ba¨cker (&)  U. Lindequist
Department of Pharmaceutical Biology, Institute of Pharmacy,
Ernst Moritz Arndt University Greifswald, Friedrich-Ludwig-
Jahn-Straße 17, 17489 Greifswald, Germany
e-mail: cbaecker@uni-greifswald.de
M. N. Drwal  R. Preissner
Structural Bioinformatics Group, Institute for Physiology,
Charite´ – University Medicine Berlin, Lindenberger Weg 80,
13125 Berlin, Germany
123
Nat. Prod. Bioprospect.
DOI 10.1007/s13659-016-0087-5
Keywords Pittosporum angustifolium  Acylated triterpene saponins  Cytotoxicity  Topoisomerase I  Docking
1 Introduction
Pittosporum angustifolium Lodd. (Pittosporaceae) is a
small tree distributed in almost all inland areas of Aus-
tralia. Different remedies prepared from aerial parts of the
plant are used in the field of traditional Aboriginal medi-
cine e.g. for the treatment of skin diseases and cough and,
furthermore, as a supportive agent for complementary
therapy strategies [1, 2]. Recently, we have extensively
investigated the phytochemistry of the seeds and leafs of P.
angustifolium, resulting in the isolation and structural
elucidation of five known polyphenols (quercetin glyco-
sides and dicaffeoylquinic acids) and 33 mono- and bis-
desmosidic triterpene saponins, of which 29 were reported
for the first time, possessing oleanane, rare 17,22-seco-
oleanolic acid and taraxastane aglycones [3–7]. Since the
biological activities of triterpene saponins are described as
manifold as their number of possible structures [8], often a
generalized cytotoxic activity but also detailed modes of
action, as well, are published [9]. In recent studies we have
screened isolated compounds of P. angustifolium for their
cytotoxic potential against three tumorigenic cell lines
(MCF7—human breast cancer, 5637—human urinary
bladder carcinoma, LN18—human glioblastoma) and one
non-tumorigenic cell line (HaCaT—human keratinocyte)
[3, 5, 7, 10]. We found, that monodesmosidic saponins of
the oleanane-type, featuring acyl-substituents like acetyl
(Ac), 2-acetoxy-2-methylbutyroyl (AcOMebu), angeloyl
(Ang) or 2-methylbutyroyl (Mebu) groups at C-21/C-22 of
the aglycone backbone showed cytotoxic activity up to the
low lM-range [3, 5, 10]. Similar results concerning those
structural elements of investigated saponins combined with
a linked cytotoxicity have also been described in the past
[11–15]. To understand the possible mechanisms of
cytotoxic and antiproliferative effects, a literature search for
structural analogues has drawn our attention to the topoi-
somerase enzymes. For example, naturally occurring topoi-
somerase I and/or II inhibitors were found among the
structural classes of alkaloids, flavonoids, naphthoquinones,
di- and triperpenes [16–19], while literature data for triter-
pene saponins is barely represented [15, 20]. Wang et al.
[15] discovered, that saponins, exhibiting high structural
similarity to the here investigated compounds, had no
influence on topoisomerase II. Instead, an inhibition of
topoisomerase I has been observed, while the aglycones of
active glycosides were without discernible impact. Encour-
aged by these outcomes, herewith we report the results of an
investigation of 10 acylated triterpene saponins (Table 1)
isolated from P. angustifolium (1-10) [3, 5, 6] and partially
from other Pittosporum species before (4, 8, 9) [21, 22] for
their potential to inhibit the human topoisomerase I via gel
based relaxation assay. We further present computational
predictions of the binding mode of the active compounds
within the topoisomerase I–DNA complex.
2 Results and Discussion
For all triterpene saponins from Pittosporum angustifolium
(1-10), acylated at C-21/C-22 (1, 2, 4-10) or rather at C-28
(3), the inhibition of human topoisomerase I was deter-
mined in a DNA relaxation assay. IC50 values in a range of
2.8–46.5 lM were generated (Table 1; Fig. 1). Most
compounds (1, 2, 4-8 and 10) showed activities comparable
to or higher (2.8–8.6 lM) than that of the positive control
camptothecin (7.4 lM), while saponins 3 and 9 were
slightly less active with IC50s of 16.8 and 46.5 lM,
respectively. Also the only tested non-cytotoxic structure
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3 [10], whose 2-methylbutyroyl acyl residue is attached to
C-28, caused an inhibition of topoisomerase I which was
relatively weaker, whereas 9, the one possessing high
cytotoxicity for all investigated cell lines [5, 10] showed the
weakest activity with 46.5 lM. Interestingly, compound 10,
possessing no hydroxyl group at C-15 and a galactose
moiety instead a glucose unit as in 9, showed a nearly ten-
fold stronger inhibition (5.0 lM) than compound 9. The
most potent inhibitor with an IC50 of 2.8 lM turned out to
be compound 8, carrying a 2-methylbutyroyl acyl residue at
C-22 and found out to be the most cytotoxic compound
tested on LN18 cells [5, 10]. Moreover, compound 8
exhibited a more potent inhibition than structure 1, pos-
sessing an angeloyl moiety (1) instead a 2-methylbutyroyl
residue (8). A finer distinction between the different patterns
of acylation at C-22/C-21 as seen for the cytotoxicity
screening [5, 10], from which more obvious tendencies or
conclusions could be summarized, have not been clearly
observed in the results of the topoisomerase I assay. Nev-
ertheless, the present data indicate that certain compounds
possess pronounced cytotoxic effects and a serious inhibi-
tion of topoisomerase I as well (compounds 1, 2, 4-8), but
also contradictory relationships (compounds 3, 9) were
observed. As a common feature of investigated structures 1-
10, all of them possess at least one 5-carbon acyl substituent
with a functional element of a keto group, in detail an
angeloyl, 2-methylbutyroyl or a partially modified derivative
like a 2-acetoxy-2-methylbutyroyl residue, either at C-28
(3), C-22 (1, 2, 5, 6, 8), C-21 (4, 7) or at both, C-21 and
C-22 (9, 10). Furthermore, acetyl groups can additionally be
attached at C-22 (4, 7) or at C-21 (5, 6). As already men-
tioned, those acyl residues seem to play an essential key role
for cytotoxicity and, beyond, we could substantiate their
importance for an inhibition of the topoisomerase I as
recently reported [15]. On top of that, sugar substitution
patterns as well as the physio-chemical environment in close
proximity to the acyl residues (hydroxy group at C-15 vs. no
substitution as seen for 10 and 9) seem to trigger a de- or
increase of an inhibitory activity.
Up to date, the binding mode of saponins and struc-
turally similar compounds acting on topoisomerase I has
not been determined. To investigate whether triterpene
saponins exhibit a similar binding mode as camptothecin,
an interfacial inhibitor interacting with the DNA (via
stacking) and protein at the DNA cleavage site [23],
molecular docking predictions of camptothecin and all
investigated saponins were performed. In contrast to
camptothecin and other known interfacial topoisomerase
inhibitors, triterpene saponins are comparably large mole-
cules with a molecular weight higher than 1 kDa. Never-
theless, a blind docking study investigating possible fits
into all cavities in the protein-DNA complex revealed that
Fig. 1 Activity of acylated triterpene saponins 1-10 on topoiso-
merase I mediated relaxation (R) of supercoiled pBR322 DNA (S) in
a dose dependent manner. Gels were stained with ethidium bromide.
Camptothecin was used as positive control. Controls topo I (-)
included supercoiled DNA without enzyme, topo I (?) contained
supercoiled DNA in the presence of enzyme. For each substance (1-
10), one of the two independent experiments is shown
C. Ba¨cker et al.
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Fig. 2 Computational prediction of binding mode of the most active
compound (8) to the topoisomerase I–DNA complex. A Interactions
between compound 8, shown as sticks, and topoisomerase I, shown as
cartoon in cyan. The interacting residues are also shown as sticks.
Compound 8 forms hydrogen bonds to the residues Asn352, Arg364
and Lys751, as indicated by yellow dotted lines. The molecule forms
also hydrophobic interactions with the side chains of Arg364, Arg634
and Ala715. B Interactions between compound 8 and DNA, shown as
green spheres. Apart from hydrophobic interactions with the DNA,
also two hydrogen bonds to the DNA bases at the cleavage site are
formed
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123
the saponins are capable of fitting into the same cavity as
camptothecin, located at the DNA cleavage site. When
analyzing the 100 docking runs for each compound, it was
noted that the majority of poses were found in a similar
orientation as indicted in Fig. 2 for the most active com-
pound (8). Thus, all triterpene saponins were predicted to
exhibit a similar binding mode. Although, due to the
absence of aromatic rings, saponins, unlike camptothecin,
cannot form stacking interactions with the DNA bases, they
are capable of crossing the DNA cleavage site and inter-
acting with the DNA via hydrophobic contacts and
hydrogen bonds. Furthermore, interactions are also
observed between the compounds and the protein residues
in the proximity of the cleavage site. In particular, the most
active compound (8) showed hydrogen bonds to the resi-
dues Arg364, Asn352 and Lys751 (Fig. 2), the former two
also interacting with other known topoisomerase interfacial
inhibitors [23–25]. However, the small differences in
topoisomerase I IC50 values could not be explained by the
presence or absence of specific protein interactions in the
docking study. Nevertheless, the investigated compounds
showed different hydrogen bond networks with the DNA
bases at the cleavage site. Further studies, involving the
experimental determination of DNA sequence preferences
of the saponin series as well as molecular dynamics sim-
ulations, mutagenesis and crystallographic experiments
could shed more light on the exact binding mode and the
structure–activity-relationship of the described compounds
in future.
Finally, it must not necessarily exist a direct connection
between these two observed biological activities resp. that
the cytotoxic effect was caused (only) by an inhibition of
topoisomerase I but it might be an involved mechanism in
cytotoxic procedures until further work corroborate or
invalidate this point of view.
3 Experimental Section
The relaxation assay on human topoisomerase I was carried
out by Inspiralis Limited, UK, according to their SOP
(standard operating procedure). All compounds were dis-
solved in DMSO and then diluted to yield concentration
ranges from 1 nM to 1 mM. Camptothecin was used as
positive control. 1 U (the amount of enzyme required to
completely relax the substrate) was incubated with 0.5 lg
supercoiled plasmid DNA (pBR322) at 37 C for 30 min in
a 30 lL reaction mixture of 20 mM Tris HCL (pH 7.5),
200 mM NaCl, 0.25 mM EDTA and 5 % glycerol. The
reaction was stopped by adding 30 lL chloroform/iso-amyl
alcohol (26:1) and 20 lL Stop Dye (40 % sucrose,
100 mM Tris HCl (pH 7.5), 10 mM EDTA, 0.5 lg/mL
bromophenol blue) before being loaded on a 0.8 % TAE
gel run for 2 h at 80 V. Then bands were visualized by
ethidium staining for 10 min and analyzed by documen-
tation equipment (Syngene, Cambridge, UK), gel scanning
software (Syngene, GeneTools) and SigmaPlot version
12.3. All assays were carried out in a final DMSO con-
centration of 10 % and were performed twice.
To predict a possible mode of action, molecular docking
studies were performed using GOLD Suite 5.2 (CCDC,
UK) with settings optimized in previous studies [24, 25].
Briefly, the crystal structure of the topotecan-topoiso-
merase I-DNA complex (PDB: 1K4T [26]) was chosen for
docking because of the best resolution among the available
structures. Rigid docking (100 runs) was performed using
the ChemPLP scoring function, a population size of 100
and a maximum of 106 operations. To investigate all pos-
sible binding modes, a blind docking was performed,
covering all protein cavities. Docking poses were analyzed
based on their orientation, the interactions formed with the
topoisomerase–DNA complex as well as the docking
scores. The root-mean-square deviation between coordi-
nates of all poses of each compound were calculated and
used for hierarchical clustering. The largest cluster at a
clustering distance of 3 A˚ was investigated further. With
the chosen settings, it was possible to re-dock camptothecin
into an orientation similar to the crystal structure pose [23,
24].
Acknowledgments We sincerely thank Dr. R. Kunze for providing
the plant material.
Compliance with Ethical Standards
Conflict of interest The authors declare no conflict of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. L.W. Cayzer, M.D. Crisp, I.R.H. Telford, Aust. Syst. Bot. 13,
845–902 (2000)
2. K.O. Gliszczynski, Patent WO 2009/037225 A2 (2009)
3. C. Ba¨cker, K. Jenett-Siems, K. Siems, M. Wurster, A. Bodtke, C.
Chamseddin, M. Cru¨semann, U. Lindequist, Planta Med. 79,
1461–1469 (2013)
4. C. Ba¨cker, K. Jenett-Siems, A. Bodtke, U. Lindequist, Biochem.
Syst. Ecol. 55, 101–103 (2014)
5. C. Ba¨cker, K. Jenett-Siems, K. Siems, M. Wurster, A. Bodtke, U.
Lindequist, Z. Naturforsch C. 69, 191–198 (2014)
6. C. Ba¨cker, K. Jenett-Siems, K. Siems, M. Wurster, A. Bodtke,
T.H.J. Niedermeyer, U. Lindequist, Z. Naturforsch B. 69,
1026–1044 (2014)
C. Ba¨cker et al.
123
7. C. Ba¨cker, K. Jenett-Siems, K. Siems, M. Wurster, A. Bodtke,
T.H.J. Niedermeyer, U. Lindequist, Z. Naturforsch B. 70,
403–408 (2015)
8. B. Dinda, S. Debnath, B.C. Mohanta, Y. Harigaya, Chem. Bio-
divers. 7, 2327–2580 (2010)
9. I. Podolak, A. Galanty, D. Sobolewska, Phytochem. Rev. 9,
425–474 (2010)
10. C. Ba¨cker, Dissertation, Ernst Moritz Arndt University (2014)
11. T. Ohtsuki, T. Miyagawa, T. Koyano, T. Kowithayakorn, N.
Kawahara, Y. Goda, M. Ishibashi, J. Nat. Prod. 71, 918–921
(2008)
12. P.K. Chan, Biochem. Pharmacol. 73, 341–350 (2007)
13. P.K. Chan, M. Zhao, C.T. Che, E. Mak, J. Nat. Prod. 71,
1247–1250 (2008)
14. W. Yuan, P. Wang, G. Deng, S. Li, Phytochemistry 75, 67–77
(2012)
15. P. Wang, S. Ownby, Z. Zhang, W. Yuan, S. Li, Bioorg. Med.
Chem. Lett. 20, 2790–2796 (2010)
16. S. Castelli, A. Coletta, I. D’Annessa, P. Fiorani, C. Tesauro, A.
Desideri, Biol. Chem. 393, 1327–1340 (2012)
17. A.R. Chowdhury, S. Sharma, S. Mandal, A. Goswami, S.
Mukhopadhyay, H.K. Majumder, Biochem. J. 366, 653–661
(2002)
18. S. Wada, A. Iida, R. Tanaka, J. Nat. Prod. 65, 1657–1659 (2002)
19. M. Fronza, E. Lamy, S. Gu¨nther, B. Heinzmann, S. Laufer, I.
Merford, Phytochemistry 78, 107–119 (2012)
20. W. Yuan, P. Wang, Z. Zhang, Z. Su, S. Li, Phytochem. Lett. 6,
106–109 (2013)
21. I. D’Acquarica, M.C. Di Giovanni, F. Gasparrini, D. Misiti, C.
D’Arrigo, N. Fagnano, D. Guarnieri, G. Iacono, G. Bifulco, R.
Riccio, Tetrahedron 58, 10127–10136 (2002)
22. R. Higuchi, T. Fujioka, M. Iwamoto, T. Komori, T. Kawasaki,
E.V. Lassak, Phytochemistry 22, 2565–2569 (1983)
23. B.L. Staker, M.D. Feese, M. Cushman, Y. Pommier, D. Zem-
bower, L. Stewart, A.B. Burgin, J. Med. Chem. 48, 2336–2345
(2005)
24. B.L. Staker, K. Hjerrild, M.D. Feese, C.A. Behnke, A.B. Burgin
Jr, L. Stewart, Proc. Natl. Acad. Sci. USA 99, 15387–15392
(2002)
25. M.N. Drwal, K. Agama, L.P. Wakelin, Y. Pommier, R. Griffith,
PLoS ONE 6, e25150 (2011)
26. M.N. Drwal, K. Agama, Y. Pommier, R. Griffith, J. Comput.
Aided Mol. Des. 27, 1037–1049 (2013)
Inhibition of DNA–Topoisomerase I by Acylated Triterpene Saponins from Pittosporum…
123
